转自：新华社 根据身体功能评分（ALSFRS-R），蔡磊已从总分48分降至个位数，进入疾病的终末期。用他自己的感 受来说，大脑无比清醒看着身体像磁铁一样被禁锢得动弹不得，时刻疼痛酸楚、麻木难忍、窒息憋闷， 却无法呼喊表达，比植物人还要残酷，连呼吸都成为一种奢望。 蔡磊表示，除基因类型外，目前全世界依然没有看到可以阻止或逆转改善病情的药物和办法，似乎有痛 苦和悲观的充分理由。 "但我并不这么看。我们正处于一个有史以来最伟大时代，我们无比幸运。"他在信中写道。 这是一个科技爆发的时代，知识的复利效应与技术范式的剧烈切换，正在重塑人类理解生命与自身的方 式。这同样是一个和平发展的时代，对整个人类文明而言，和平、发展与繁荣并非常态，而是来之不易 的短暂窗口。 蔡磊表示，2026年是"十五五"规划的开局之年，也是他们期待重大突破的一年。现在的他，依靠眼控仪 坚持每天工作十余个小时，搭建科研平台，链接上万病友，推动药物研发……"分秒必争"地向攻克绝症 的目标冲锋。 2025年，蔡磊团队通过与全球60多个顶尖科研团队深入交流，与50多家生物科技公司以及十余家医院深 度合作，推动了近百个渐冻症科研合作项目，助力15个药物管线 ...

马斯克：2026年将"大规模生产"脑机接口设备 马斯克说，该设备的电极丝将直接穿过硬脑膜，而无需将其切除，此举意义重大。 "神经连接"公司2024年1月28日完成了该公司首例脑机接口设备人体移植。截至2025年9月，全球已有12人植 入"神经连接"设备，累计使用时间达2000天，总使用时长超过1.5万小时。 该公司近期表示，临床试验参与者已将控制能力扩展到实体设备，例如辅助型机器人手臂。随着时间推移，公 司计划进一步拓展可通过"神经连接"控制的设备范围。 美国企业家埃隆·马斯克2025年12月31日在社交媒体上表示，其脑机接口公司"神经连接"将于2026年开始对脑 机接口设备进行"大规模生产"，并转向"更加精简和几乎完全自动化的外科手术流程"。 F 责编：汪云鹏 校对：杨立林 百万用户都在看 深夜！16倍大牛股，突发！ 刚刚，飙涨201%！ 2026年新年献词｜顺流逆流，守护我们内心的罗盘！ 市值腰斩！巴菲特"踩雷"，给我们敲响什么警钟？ 独家揭秘！新股未上市先套现，中签之前也能买卖！ 违法和不良信息举报电话：0755-83514034 邮箱：bwb@stcn.com 券中社 × 券商中国 券 中 社 扫码下 ...

Core Viewpoint - The article discusses the development of a novel high-throughput screening technology called FOCAS, which enables the functional dissection of individual m6A sites in mRNA, significantly enhancing the understanding of m6A's role in gene expression regulation, particularly in cancer [3][11]. Group 1: m6A Modification and Its Importance - m6A is the most prevalent chemical modification in mRNA, regulating gene expression without altering RNA sequences [2]. - The m6A modification process is controlled by three types of proteins: "Writers" (METTL3/METTL14 complex), "Erasers" (FTO, ALKBH5), and "Readers" (YTHDF family proteins) [2]. Group 2: FOCAS Technology Development - FOCAS is based on the CRISPR-dCas13b system and FTO, allowing for high-throughput, site-specific functional screening of m6A [4][8]. - This technology provides a powerful and unbiased method for functional analysis of m6A, laying a solid foundation for future basic research and therapeutic development [4][11]. Group 3: Key Findings from the Research - A total of 4,475 genes were identified whose expression is regulated by m6A across four cancer cell lines, affecting cell survival and proliferation [9]. - Many identified m6A-regulated genes are newly associated with cancer, exhibiting dynamic expression changes [9]. - The role of m6A within the same gene varies depending on the cellular environment and the "Reader" proteins involved, indicating a complex regulatory mechanism [9]. - The study identified "universal" m6A patterns present in all cell lines, particularly in transcription-related genes, and "specific" m6A patterns unique to certain cell types, especially in non-coding RNAs [9]. - An extensive interaction network between the m6A modification layer and the gene expression layer was revealed in the SMMC-7721 human liver cancer cell line [9].

Core Insights - The article highlights the innovative employment initiatives in Wuhan's East Lake New Technology Development Zone, particularly focusing on the establishment of community-based employment supermarkets that provide training and job matching services for residents [6][8][19] Group 1: Employment Supermarket Initiatives - The employment supermarket in Huashan Street has identified 1,042 local enterprises and published 232 recruitment weeks, offering 2,075 job positions and successfully recommending employment for 1,397 individuals [6] - The supermarket initially targeted older job seekers but has expanded to include full-time mothers and young skill enhancers, adapting its training programs to meet the evolving needs of the community [6][8] - The employment supermarket aims to provide a full chain of support from skill training to job matching and micro-entrepreneurship incubation, with courses evolving to include modern skills like AI and short video production [6][8] Group 2: Community Engagement and Job Matching - The "1+11" employment service network includes one central employment supermarket and eleven community "stations," enhancing accessibility to job services for residents [8] - The "daily micro-recruitment" model creates a "15-minute" smart employment service circle, delivering job information directly to residents through community WeChat groups [8][19] - The focus on precise job matching is supported by a comprehensive employment service grid system, ensuring that job seekers receive tailored job recommendations [8] Group 3: Support for Startups and Innovation - The Hubei Youth Innovation Park offers low-cost office space for startups, charging only 200 yuan per month per workstation, which significantly reduces operational costs for new businesses [13][14] - The park has successfully incubated 300 enterprises, with 80 graduating, demonstrating the effectiveness of its low-cost entry and high-value service model [14] - Collaboration with local universities enhances the park's ability to attract high-quality technology projects and talent, fostering a vibrant entrepreneurial ecosystem [14][16] Group 4: Talent Attraction and Economic Growth - Wuhan's various talent initiatives, such as the "3551 Optics Valley Talent Plan," aim to attract skilled professionals and support the growth of small and medium-sized tech enterprises [16][17] - In 2023, the East Lake New Technology Development Zone added over 45,000 jobs, accounting for one-sixth of the total new employment in Wuhan, indicating a robust job market [17][19] - The region's focus on key industries like optoelectronic information and health care aims to attract over 50,000 college graduates by 2025, addressing talent shortages and promoting high-quality employment [17]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Touyun Biotech Group Limited 透 雲 生 物 科 技 集 團 有 限 公 司 （於百慕達註冊成立的有限公司） （股份代號：1332） 有關解決核數保留意見行動計劃執行情況的季度更新 本 公 告 乃 由 透 雲 生 物 科 技 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團」）董事（「董事」）會（「董事會」）根據香港聯合交易所有限公司證券上市規則（「上 市規則」）第13.09 (2)條及香港法例第571章證券及期貨條例第XIVA部內幕消息條文 （ 定義見上市規則 ）而作出。 茲 提 述 本 公 司 截 至 2024 年 12 月 31 日 止 年 度 的 年 報（「 2024 年 年 報 」）。 除 另 有 指 明 外，本文所用詞彙與2024年年報所界定者具有相同涵 ...

南财智讯12月31日电，优宁维公告，公司于2025年12月30日召开第四届董事会第十次会议，审议通过了 《关于部分募投项目结项并将节余募集资金永久补充流动资金的议案》。公司首次公开发行股票募投项 目中的"爱必信（上海）生物科技有限公司实验室建设项目"和"上海乐备实生物技术有限公司实验室调 整项目"已达到预定可使用状态，拟进行结项。截至2025年11月30日，上述项目节余募集资金合计 235.01万元（实际金额以资金转出当日专户余额为准）。公司拟将该节余资金永久补充流动资金，用于 日常生产经营活动。节余资金划转完成后，公司将注销相关募集资金专用账户，相关监管协议将予以终 止。 ...

Core Viewpoint - The emergence of Maya Kawana, the daughter of Masayoshi Son, as a potential successor in the SoftBank empire raises questions about the future leadership of the company as many second-generation heirs begin to take over in the global investment landscape [2][3]. Group 1: Maya Kawana's Background and Career - Maya Kawana, born in April 1981, has recently joined the biotech company Spiber, which has a valuation of $1.2 billion, marking her first public role in the business world [2][11]. - She graduated from Keio University in 2000 and worked at Goldman Sachs for four years, focusing on corporate financing and mergers and acquisitions, where she developed a strong work ethic [5][7]. - After a brief hiatus as a full-time mother, she returned to the business world, taking on leadership roles in various companies, including serving as CEO of BOLD Corporation and General Manager at Afiniti Japan [9][12]. Group 2: Spiber and Its Strategic Importance - Spiber utilizes microbial fermentation to produce synthetic spider silk protein, aligning with Masayoshi Son's vision for sustainable technology [11]. - The company is facing significant financial challenges, with a projected net loss of 29.517 billion yen (approximately 1.33 billion RMB) in 2024, highlighting the urgency of Kawana's role in stabilizing and promoting the company's growth [12]. - Kawana aims to leverage her resources to enhance Spiber's market position and communicate its core advantages effectively [12]. Group 3: SoftBank's Leadership Transition - Masayoshi Son, at 68 years old, has expressed intentions to continue leading SoftBank for another decade while searching for a suitable successor [16][18]. - The company is undergoing a critical transformation, focusing on artificial intelligence and technology investments, which necessitates a leader capable of navigating these opportunities [18]. - Son has previously attempted to groom potential successors, but many have left the company, indicating the challenges in establishing a clear leadership path [18].

Core Insights - In 2025, China made significant technological breakthroughs across various fields, contributing to high-quality development and global progress in civilization [1][2] Group 1: Technological Innovations - The "artificial sun" achieved a world record of 1 million degrees Celsius for 1066 seconds, marking a significant step in nuclear fusion research [9] - The successful launch of the Tianwen-2 probe initiated China's first asteroid exploration mission, enhancing capabilities in deep space exploration [10] - The DeepSeek AI model broke traditional paths by optimizing algorithms to achieve top performance with limited computing power, promoting an open ecosystem for global developers [7] Group 2: Scientific Research Achievements - The first large-area production of two-dimensional metal materials was achieved, marking a new frontier in material science [3] - Research on lunar samples from the far side of the moon revealed new insights into its geological history, challenging previous understandings [4] - The Jiangmen Neutrino Experiment (JUNO) achieved a measurement precision 1.5 to 1.8 times better than the previous international standard, advancing the study of neutrinos [4] Group 3: Economic Impact and Industry Development - The integration of AI technologies across various sectors, including healthcare and transportation, is driving high-quality development and enhancing productivity [12][14] - The approval of 69 innovative drugs in 2025 set a new record, reflecting the rapid advancement in the pharmaceutical industry [13] - The promotion of carbon capture technology in the cement industry and digital transformation in the steel industry are part of a broader shift towards sustainable practices [14] Group 4: Strategic Initiatives - The establishment of a comprehensive innovation system is underway, with a focus on self-reliance in technology and the cultivation of new productive forces [15] - The development of advanced technologies such as brain-computer interfaces and quantum computing is positioning China as a leader in these fields [8]

Core Viewpoint - The company Insilico Medicine, driven by generative artificial intelligence, successfully listed on the Hong Kong Stock Exchange, raising a total of HKD 2.277 billion, marking the highest fundraising for a biotech IPO in Hong Kong this year [1][3]. Group 1: IPO Details - Insilico Medicine's IPO was priced at HKD 24.05 per share, with an opening increase of 45.5% to HKD 35.00 per share [3]. - The IPO was co-sponsored by Morgan Stanley, CICC, and GF Securities, with a total issuance of 94.6905 million shares, where the Hong Kong public offering accounted for 10% and was oversubscribed by approximately 1,427.37 times, securing over HKD 328.349 billion in subscription funds [5]. - The international offering accounted for 90% and was oversubscribed by 26.27 times, setting a record for non-18A Hong Kong healthcare IPOs [5]. Group 2: Investor Participation - Insilico Medicine attracted 15 cornerstone investors, including Eli Lilly, Tencent, Temasek, Schroders, UBS, Oak Tree Capital, E Fund, and Taikang Life, enhancing its credibility in the global pharmaceutical and investment landscape [6]. - Notably, Eli Lilly and Tencent participated as cornerstone investors for the first time in a biotech company, while Oak Tree Capital returned to the Hong Kong biotech market as a cornerstone investor [6]. Group 3: Company Overview and Innovation - Insilico Medicine utilizes its proprietary Pharma.AI platform and advanced automated laboratories to accelerate drug discovery, focusing on unmet medical needs in areas such as fibrosis, oncology, immunology, pain, obesity, and metabolic disorders [7]. - The company has ten molecules that have received clinical trial approval, with Rentosertib being the most advanced candidate for treating idiopathic pulmonary fibrosis, having completed Phase 2a clinical studies with positive results [7]. - Compared to traditional drug development timelines of approximately 4.5 years, Insilico Medicine has reduced the average time from project initiation to clinical candidate nomination to 12 to 18 months for over 20 self-developed projects from 2021 to 2024 [7][8]. Group 4: Future Plans and Funding Allocation - Following the IPO, Insilico Medicine plans to allocate approximately 48% of the raised funds for further clinical development of key pipeline candidates, 20% for early drug discovery and development, 15% for developing innovative generative AI models and related validation studies, 12% for further development and expansion of automated laboratories, and 5% for operational funds and other general corporate purposes [9].

齐鲁晚报.齐鲁壹点闫丽君尹睿魏银科 编者按： 近年来，烟台以打造绿色低碳高质量发展示范城市为远景目标，将新质生产力、绿色低碳高质量发展转 化为烟台人可感可知的日常场景。为讲述2025年烟台经济民生领域取得的卓越成绩以及烟台全力打造绿 色低碳高质量发展示范城市的亮眼举措，烟台市委网信办、齐鲁晚报.齐鲁壹点烟台融媒中心联合推 出"网语烟台与新质握手"网络宣传引导活动，以具体的场景和真实的故事，连接产业进步与民间共鸣， 共述一座城的焕新之旅。 在烟台高新区，有一种"炼金术"正在上演：原本只能被当作饲料、每吨身价不过六七百元的虾蟹壳，经 过一番神奇的"洗礼"，摇身一变成了价值20多万元一吨的"香饽饽"；而一旦它们被施入田间地头，创造 的经济价值更是能再翻1000多倍。 这番操作背后化腐朽为神奇的"魔术师"，就是烟台固特丽生物科技股份有限公司。作为深耕细分赛道 的"专精特新"企业，固特丽用一个个颠覆性的技术，打通"海洋废弃物-高价值产品-农业赋能"的循环链 条，生动诠释了什么是新质生产力——它不仅是高科技的角逐，更是绿色、高效与智慧的完美融合。 "无钙补钙"：打破30年的"铁律" "固特丽的产品核心成分并非传统氮磷钾肥 ...